Joseph Lyon - Corcept Therapeutics Chief Officer
| CORT Stock | USD 31.93 1.38 4.14% |
Insider
Joseph Lyon is Chief Officer of Corcept Therapeutics Incorporated
| Age | 46 |
| Address | 149 Commonwealth Drive, Menlo Park, CA, United States, 94025 |
| Phone | 650 327 3270 |
| Web | https://www.corcept.com |
Joseph Lyon Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joseph Lyon against Corcept Therapeutics stock is an integral part of due diligence when investing in Corcept Therapeutics. Joseph Lyon insider activity provides valuable insight into whether Corcept Therapeutics is net buyers or sellers over its current business cycle. Note, Corcept Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Corcept Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joseph Lyon over two months ago Disposition of 5443 shares by Joseph Lyon of Corcept Therapeutics at 26.0011 subject to Rule 16b-3 |
Corcept Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.1197 % which means that it generated a profit of $0.1197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2191 %, meaning that it created $0.2191 on every $100 dollars invested by stockholders. Corcept Therapeutics' management efficiency ratios could be used to measure how well Corcept Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024. Return On Capital Employed is likely to gain to 0.22 in 2024. At this time, Corcept Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 652.6 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 349.7 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| MPH MD | Connect Biopharma Holdings | 54 | |
| Ian Leitch | Opthea | 61 | |
| David Grainger | Centessa Pharmaceuticals PLC | 55 | |
| James Goding | Opthea | N/A | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| MD MBA | Opthea | N/A | |
| Paul Little | Eledon Pharmaceuticals | 59 | |
| MD MSc | Centessa Pharmaceuticals PLC | 64 | |
| MAICD MAICD | Opthea | 48 | |
| Steven Chan | Connect Biopharma Holdings | 52 | |
| Stacy Markel | Nuvation Bio | 59 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Malinda Longphre | Connect Biopharma Holdings | N/A | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| David Hovland | Eledon Pharmaceuticals | N/A | |
| Michelle Doig | Nuvation Bio | 46 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Christopher MD | Nuvalent | 55 | |
| David MD | Nuvation Bio | 54 | |
| Lei Sun | Connect Biopharma Holdings | 60 | |
| CFA CFA | Travere Therapeutics | 40 | |
Management Performance
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.12 |
Corcept Therapeutics Leadership Team
Elected by the shareholders, the Corcept Therapeutics' board of directors comprises two types of representatives: Corcept Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Corcept. The board's role is to monitor Corcept Therapeutics' management team and ensure that shareholders' interests are well served. Corcept Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Corcept Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hazel Hunt, Chief Officer | ||
| Amy Flood, Chief Officer | ||
| Joseph MD, President, CoFounder | ||
| William PharmD, Chief Officer | ||
| Roberto Vieira, President Oncology | ||
| Gary Robb, CFO, Chief Accounting Officer and Secretary | ||
| Joseph Lyon, Chief Officer | ||
| Monica Tellado, President Markets | ||
| Atabak Mokari, CFO Treasurer | ||
| Sean Maduck, Senior Vice President - Commercial |
Corcept Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Corcept Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 2.91 B | ||||
| Shares Outstanding | 104.11 M | ||||
| Shares Owned By Insiders | 11.38 % | ||||
| Shares Owned By Institutions | 91.91 % | ||||
| Number Of Shares Shorted | 19.8 M | ||||
| Price To Earning | 30.07 X |
Pair Trading with Corcept Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corcept Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corcept Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Corcept Stock
| 0.8 | TOVX | Theriva Biologics | PairCorr |
| 0.78 | PRGO | Perrigo Company Buyout Trend | PairCorr |
| 0.66 | ATXI | Avenue Therapeutics | PairCorr |
| 0.51 | ANVS | Annovis Bio Earnings Call Today | PairCorr |
| 0.43 | NEO | NeoGenomics | PairCorr |
The ability to find closely correlated positions to Corcept Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corcept Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corcept Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corcept Therapeutics Incorporated to buy it.
The correlation of Corcept Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corcept Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corcept Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corcept Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.